AssetWatch

Predictive maintenance for pharma uptime

Dublin, Ohio, United States

Other Supply Chain Facilities & Asset ManagementSeries C

AssetWatch is a company providing end-to-end condition monitoring and AI-driven predictive maintenance solutions.

AssetWatch hero image

Shareable draft

Check out AssetWatch on @MedStartr Today AssetWatch is a company providing end-to-end condition monitoring and AI-driven predictive maintenance solutions. #PharmaceuticalHealthcareManufacturing #Plastics #PulpPaperPackaging #WaterWastewater #Chemicals #FoodBeverage #ForestryBuildingMaterials #MetalsProcessing #MiningAggregates #TextilesAndApparel #Other #SupplyChainManufacturingDistribution #FacilitiesAssetManagement #MedMo #MedStartrVentures

https://www.medstartr.ai/s/EJ6e9EMCSr4

Get Involved in AssetWatch

How We Help

Problem Statement

Unplanned downtime and sub-optimal operations in industrial and manufacturing sectors.

Core Technology

Wireless sensors, AI-driven analytics, Centralized platform for real-time monitoring

Key Differentiators

End-to-end condition monitoring; AI-driven predictive maintenance solutions; Wireless sensors; AI-driven analytics; Expert insights; Prevents unplanned downtime

Target Customers

Global manufacturers across industrial sectors including pharmaceutical & healthcare, plastics, pulp & paper, water & wastewater, chemicals, food & beverage, forestry & building materials, metals & processing, mining & aggregates, and textiles & apparel.

Product Stage

Company Info

Business Model: B2B SaaS
Founded: 2014
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: assetwatch.com

Disease Areas

Pharmaceutical & Healthcare Manufacturing Plastics Pulp, Paper & Packaging Water & Wastewater Chemicals Food & Beverage Forestry & Building Materials Metals & Processing Mining & Aggregates Textiles and Apparel

Technologies

Wireless SensorsCommunication HubsAI-driven AnalyticsPredictive MaintenanceRemote Condition MonitoringIoTPredictive AnalyticsAsset TrackingAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

Deployed across 20+ pharmaceutical and healthcare manufacturing facilities. Documented case studies: fan component replacement ($58k saved), agitator bearing replacement ($150k saved), motor replacement ($250k saved). Operates within FDA-regulated pharma manufacturing environments.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of AssetWatch?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.